IL1B and lung disorder: Mechanistically, we demonstrated here in vitro and in vivo in three independent models (two involving mice given IAV +/– P.a, and one involving mice given IAV +/– IL-1β) that IAV pre-treatment promoted secondary PAO1-mediated lung disease or augmented IL-1β-mediated inflammation, by enhancing deleterious inflammatory responses.